The JAK-STAT signaling-related signature serves as a prognostic and predictive biomarker for renal cell carcinoma immunotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies a Janus kinase/signal transduction and activator transcriptional (JAK/STAT) pathway signature to predict renal cell carcinoma (RCC) patient outcomes and response to immune checkpoint inhibitors (ICIs). High-risk patients show poorer prognosis and less benefit from immunotherapy.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Renal cell carcinoma (RCC) presents a significant challenge due to poor prognosis and high metastasis rates.
- Current immunotherapy for advanced RCC yields unsatisfactory outcomes.
- Predictive biomarkers are crucial for guiding treatment strategies and improving patient survival.
Purpose Of The Study
- To develop a Janus kinase/signal transduction and activator transcriptional (JAK/STAT) pathway-related gene signature for predicting renal cell carcinoma (RCC) patient prognosis.
- To assess the efficacy of this signature in predicting response to immune checkpoint inhibitors (ICIs).
- To guide the development of effective combination therapies for RCC.
Main Methods
- Screened 25 differentially expressed genes (DEGs) enriched in the JAK-STAT pathway in RCC samples.
- Identified 11 key genes correlating with Kidney Clear Cell Carcinoma (KICC) patient outcomes.
- Utilized these genes to classify patients into high-risk and low-risk groups and performed immunohistochemistry (IHC).
Main Results
- A JAK-STAT-related risk score was developed, correlating with KIRC clinicopathologic factors.
- High-risk patients exhibited poorer prognosis, increased protumor immune cell infiltration, and reduced benefit from immunotherapy.
- JAK3 and STAT4 expression was elevated in RCC tumors and positively associated with T stage.
Conclusions
- The JAK-STAT signaling pathway plays a critical role in RCC tumor immunity.
- The developed risk score accurately predicts RCC patient survival and response to ICIs.
- Targeting the JAK-STAT pathway in combination with immune checkpoints offers a potential therapeutic strategy for RCC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...